Non-erythropoietic erythropoietin helix-B-derived peptide; generic name cibinetide
PRODUCT PROFILE
ARA-290 (Cibinetide)
£72.00
ARA-290 (Cibinetide) is non-erythropoietic erythropoietin helix-b-derived peptide; generic name cibinetide. Researchers examine it in relation to small-fibre neuropathy, tissue-protection and inflammatory repair signalling.
Why it is distinct
Separates tissue-protective EPO signalling from red-blood-cell production.
- Evidence stageClinical research
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
ARA-290 (Cibinetide) is non-erythropoietic erythropoietin helix-b-derived peptide; generic name cibinetide. Researchers examine it in relation to small-fibre neuropathy, tissue-protection and inflammatory repair signalling.
Research focus+
Researchers study nerve pain, inflammation and repair, including small-fibre neuropathy. It remains investigational.
How the mechanism differs+
Targets the proposed innate-repair receptor complex without activating the erythropoietic pathway of full EPO.
Evidence and limitations+
Early phase human trials in neuropathy and inflammatory conditions exist; it remains investigational.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study nerve pain, inflammation and repair, including small-fibre neuropathy. It remains investigational.
Targets the proposed innate-repair receptor complex without activating the erythropoietic pathway of full EPO.
Separates tissue-protective EPO signalling from red-blood-cell production.
Early phase human trials in neuropathy and inflammatory conditions exist; it remains investigational.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Cartalax
£46.0020 mgBatch file pendingCartilage-cell focus, rather than BPC-157’s broader repair signalling or GHK-Cu’s collagen/copper biology.
UnavailableAsk about availability -
Early human evidence
Thymosin Beta-4
£62.0010 mgBatch file pendingFull-length endogenous thymosin beta-4 with broader actin biology, rather than the shorter TB-500-style material.
UnavailableAsk about availability -
Preclinical
TB-500
£32.99Batch file pendingTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket -
Preclinical
BPC-157 + TB-500
Price range: £42.99 through £79.995 mg + 5 mg | 10 mg + 10 mgBatch file pendingThe combination places a gastric-peptide-derived experimental material beside an actin-regulatory thymosin pathway, rather than combining two versions of…
AvailableAdd to basket This product has multiple variants. The options may be chosen on the product page